Genetic Markers Predict Primary Non-Response and Durable Response to Anti-TNF Biologic Therapies in Crohn's Disease

American Journal of Gastroenterology

Volumn 111, Issue 12, 2016, Pages 1816-1822

  Barber, Grant E ^a   Yajnik, Vijay ^a   Khalili, Hamed ^a   Giallourakis, Cosmas ^a   Garber, John ^a   Xavier, Ramnik ^a   Ananthakrishnan, Ashwin N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; INFLIXIMAB; ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR;

ADULT; ALLELE; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE DURATION; DRUG DOSE REDUCTION; FEMALE; GENETIC ASSOCIATION STUDY; GENETIC MARKER; GENETIC MODEL; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CASE CONTROL STUDY; GENETICS; GENOTYPE; PHARMACOGENETIC VARIANT; REGISTER; RETROSPECTIVE STUDY; TIME FACTOR; TREATMENT FAILURE; YOUNG ADULT;

ADALIMUMAB; ADOLESCENT; ADULT; ALLELES; ANTI-INFLAMMATORY AGENTS; CASE-CONTROL STUDIES; CERTOLIZUMAB PEGOL; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MALE; PHARMACOGENOMIC VARIANTS; POLYMORPHISM, SINGLE NUCLEOTIDE; REGISTRIES; RETROSPECTIVE STUDIES; SMOKING; TIME FACTORS; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84986550753     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2016.408     Document Type: Article

References (32)

1. Cosnes J, Gower-Rousseau C, Seksik P et al. Epidemiology and natural history of infl ammatory bowel diseases. Gastroenterology 2011; 140: 1785-94.
2. D'Haens GR, Panaccione R, Higgins PD et al. Th e London Position Statement of the World Congress of Gastroenterology on Biological Th erapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response Am J Gastroenterol 2011; 106: 199-212.
3. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in infl ammatory bowel diseases: defi nitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66.
4. Chowers A, Sturm A, Sans M et al. Report of the ECCO workshop on anti-TNF therapy failures in infl ammatory bowel diseases: biological roles and eff ects of TNF and TNF antagonists. J Crohns Colitis 2010; 4: 367-76.
5. Gisbert JP, Panes J. Loss of response and requirement of infl iximab dose intensifi cation in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
6. Dideberg V, Louis E, Farnir F et al. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infl iximab in a large cohort study. Pharmacogenet Genomics 2006; 16: 369-73.
7. Hlavaty T, Pierik M, Henckaerts L et al. Polymorphisms in apoptosis genes predict response to infl iximab therapy in luminal and fi stulizing Crohn's disease. Aliment Pharmacol Th er 2005; 22: 613-26.
8. Jurgens M, Laubender RP, Hartl F et al. Disease activity, ANCA, and IL23R genotype status determine early response to infl iximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105: 1811-9.
9. Louis E, El Ghoul Z, Vermeire S et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infl iximab in Crohn's disease. Aliment Pharmacol Th er 2004; 19: 511-9.
10. Mascheretti S, Hampe J, Kuhbacher T et al. Pharmacogenetic investigation of the TNF/TNF-receptor system in patients with chronic active Crohn's disease treated with infl iximab. Pharmacogenomics J 2002; 2: 127-36.
11. Pierik M, Vermeire S, Steen KV et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in infl ammatory bowel disease and their association with response to infl iximab. Aliment Pharmacol Th er 2004; 20: 303-10.
12. Siegel CA, Melmed GY. Predicting response to anti-TNF agents for the treatment of crohn's disease. Th erap Adv Gastroenterol 2009; 2: 245-51.
13. Taylor KD, Plevy SE, Yang H et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001; 120: 1347-55.
14. Urcelay E, Mendoza JL, Martinez A et al. IBD5 polymorphisms in infl ammatory bowel disease: association with response to infl iximab. World J Gastroenterol 2005; 11: 1187-92.
15. Vermeire S, Louis E, Rutgeerts P et al. NOD2/CARD15 does not influence response to infl iximab in Crohn's disease. Gastroenterology 2002; 123: 106-11.
16. Koder S, Repnik K, Ferkolj I et al. Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients. Pharmacogenomics 2015; 16: 191-204.
17. Ananthakrishnan AN, Huang H, Nguyen DD et al. Diff erential eff ect of genetic burden on disease phenotypes in Crohn's disease and ulcerative colitis: analysis of a North American cohort. Am J Gastroenterol 2014; 109: 395-400.
18. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-75.
19. Jostins L, Ripke S, Weersma RK et al. Host-microbe interactions have shaped the genetic architecture of infl ammatory bowel disease. Nature 2012; 491: 119-24 (in press).
20. Dubinsky MC, Mei L, Friedman M et al. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric infl ammatory bowel disease. Infl amm Bowel Dis 2010; 16: 1357-66.
21. Niess JH, Klaus J, Stephani J et al. NOD2 polymorphism predicts response to treatment in Crohn's disease-fi rst steps to a personalized therapy. Dig Dis Sci 2012; 57: 879-86.
22. Mascheretti S, Hampe J, Croucher PJ et al. Response to infl iximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: an analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002; 12: 509-15.
23. Bertin J, Wang L, Guo Y et al. CARD11 and CARD14 are novel caspase recruitment domain (CARD)/membrane-associated guanylate kinase (MAGUK) family members that interact with BCL10 and activate NF-kappa B. J. Biol Chem 2001; 276: 11877-82.
24. Nagar M, Jacob-Hirsch J, Vernitsky H et al. TNF activates a NF-kappaBregulated cellular program in human CD45RA-regulatory T cells that modulates their suppressive function. J Immunol 2010; 184: 3570-81.
25. Liu C, Xia X, Wu W et al. Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infi ltration in Crohn's disease. Clin Exp Immunol 2013; 173: 102-11.
26. Keino H, Watanabe T, Taki W et al. Eff ect of infl iximab on gene expression profi ling in Behcet's disease. Invest Ophthalmol Vis Sci 2011; 52: 7681-6.
27. Pittoni V, Bombardieri M, Spinelli FR et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infl iximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. Ann Rheum Dis 2002; 61: 723-5.
28. Toedter G, Li K, Marano C et al. Gene expression profi ling and response signatures associated with diff erential responses to infl iximab treatment in ulcerative colitis. Am J Gastroenterol 2011; 106: 1272-80.
29. Vermeire S, Louis E, Carbonez A et al. Demographic and clinical parameters infl uencing the short-term outcome of anti-tumor necrosis factor (infl iximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-63.
30. Colombel JF, Sandborn WJ, Reinisch W et al. Infl iximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
31. Teshima CW, Th ompson A, Dhanoa L et al. Long-term response rates to infl iximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009; 23: 348-52.
32. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infl iximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.